主持国家自然科学基金、中国博士后基金特别资助等项目6项,获山东省泰山学者青年专家、国家资助博士后研究人员计划、福建省高层次人才等荣誉。以第一/通讯作者在Gut (2025,2024),Molecular Therapy等领域内权威期刊发表论著11篇,持有发明专利4项。
1. 肝病基础与转化治疗研究
1. 林曹瑞. Glycine Enhances Satellite Cell Proliferation, Cell Transplantation, and Oligonucleotide Efficacy in Dystrophic Muscle. Molecular Therapy, 2020.
2. 林曹瑞. MOTS‐c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice. EMBO Molecular Medicine, 2021.
3. 林曹瑞. Cardio-respiratory and phenotypic rescue of dystrophin/utrophin-deficient mice by combination therapy. EMBO Reports, 2022.
4. 林曹瑞. Novel function of MOTS-c in mitochondrial remodeling contributes to its antiviral role during HBV infection. GUT, 2024.
5. 林曹瑞. Therapeutic inhibition of HBsAg and HBV cccDNA through a novel phased combination treatment: glycine and interferon-α. GUT, 2025.
1. 线粒体来源短肽MOTS-c介导mtRNA激活RIG-I-MAVS信号抑制HBV复制及其在CHB中的诊断价值研究, 2023-01-01